News | June 15, 2008

Cardinal Health to Open Multiple Manufacturing Facilities for PET Imaging Agents

June 16, 2008 - Cardinal Health will open three additional Positron Emission Tomography (PET) radiopharmaceutical manufacturing facilities near its existing nuclear pharmacy locations this year, the company said today at SNM 2008.

These manufacturing facilities use cyclotrons to produce fluorine-18 (F-18), the radioactive precursor needed to create fluorodeoxyglucose (FDG), the PET imaging agent commonly used to diagnose various diseases. FDG’s relatively short half-life of just under two hours makes it challenging to efficiently distribute the product over great distances.

By locating cyclotrons near its nuclear pharmacy sites, Cardinal Health is able to efficiently distribute FDG to a greater number of hospitals, clinics and research facilities using its comprehensive fleet and logistics capabilities.

The company currently operates 22 cyclotrons and distributes PET products through nearly half of its more than 150 U.S. nuclear pharmacy locations. This year Cardinal Health will open three new cyclotrons located in Tampa, FL,, Hartford, CN,. and Louisville, KY.

In addition to FDG, the company’s new cyclotrons will produce a variety of other PET imaging agents to support oncology, neurology and cardiac imaging procedures.

The company’s new cyclotron facility in Tampa will be its third in the state, supplementing existing radiopharmaceutical manufacturing sites in Ft. Lauderdale and Orlando. It will be located on the campus of the H. Lee Moffitt Cancer & Research Center, where it will support research and clinical programs in oncology. It will also supply imaging agents to other customers in the greater Tampa area.

The company’s new facility in Hartford will house the first commercial cyclotron in the state; and its Louisville cyclotron will be the company’s first in Kentucky. The Hartford site will enhance Cardinal Health’s ability to serve nuclear pharmacy customers in New England, an area that is also serviced from its Boston and East Rutherford, NJ, sites. The Louisville cyclotron will join Cardinal Health’s Cincinnati manufacturing facility in servicing central and northern Kentucky. It will also join the company’s St. Louis site in servicing western Kentucky.

For more information: www.cardinalhealth.com

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
PET
Feature | Imaging | April 11, 2017 | By Greg Freiherr
Positron emission tomography (PET) and other brain assessments
Overlay Init